Everysecondcounts!™🔒 SSL Verified

Table of Contents

• ↓ Here for you, every second
• ↓ Locations
• ↓ Utility
• ↓ Main navigation
• ↓ Vanessa
• ↓ It’s  . Today, right at this moment, we’re hard at work for patients like Vanessa who have a critical therapeutic need. We approach everything we do with a sense of urgency because, for them, we understand the clock is ticking—and that every second makes a difference.
• ↓ Top Alternatives to kiniksa.com

6-Month Traffic Trend Estimate

Official Contact & Profiles

Visual representation extracted from kiniksa.com

Content Snippets from kiniksa.com

"PASTORALE, the pivotal Phase 3 trial in recurrent pericarditis evaluating KPL-387*, is enrolling and dosing patients. KPL-387 is an investigational monoclonal antibody IL-1 receptor antagonist in a liquid formulation, with a target profile of once-monthly subcutaneous dosing."

"*KPL-387 is an investigational product. The efficacy and safety of KPL-387 have not been evaluated by any regulatory authority."

"View webcast of Chief Executive Officer and Chairman Sanj K. Patel’s presentation on Kiniksa’s portfolio of immune-modulating assets."

"Living with a debilitating disease brings questions that go far beyond the symptoms—there’s the fear and frustration of not knowing when, or if, there will ever be an answer. That’s why we’re relentless about making every moment matter at Kiniksa: because every second brings us closer to creating a better future for patients. Hear stories from the people who live with the uncertainty of these diseases every day."

Key Topics & Focus Areas for kiniksa.com:

Here for you, every second

Locations

Utility

Main navigation

Vanessa

It’s  . Today, right at this moment, we’re hard at work for patients like Vanessa who have a critical therapeutic need. We approach everything we do with a sense of urgency because, for them, we understand the clock is ticking—and that every second makes a difference.